Mackenzie Financial Corp Aurinia Pharmaceuticals Inc. Transaction History

Mackenzie Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 08, 2021	SELL	$10.93 - $23.55 $304,695 - $656,503	-27,877 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$10.0 - $14.52 $5,740 - $8,334	574 Added 2.1%	27,877 $361,000
Q1 2021 May 14, 2021	BUY	$12.3 - $18.73 $185,065 - $281,811	15,046 Added 122.75%	27,303 $355,000
Q4 2020 Feb 10, 2021	BUY	$12.94 - $16.05 $5,266 - $6,532	407 Added 3.43%	12,257 $169,000
Q3 2020 Nov 13, 2020	BUY	$13.19 - $16.66 $156,301 - $197,421	11,850 New	11,850 $175,000

207

58.6M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.27B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.